Compound library / Healing & recovery / Bone Health
Synthetic PTHrP(1-34) analogue, FDA-approved for postmenopausal osteoporosis with high fracture risk; explored in biohacking circles for bone remodeling. Acts preferentially on the anabolic arm of the PTH pathway.
| Category | Bone Health |
|---|---|
| Regulatory standing | No approved product cited |
| Typical route | Subcutaneous |
| Half-life | ~1.7 hours |
| Common dose range | 80 mcg once daily (approved dose); research use mirrors this |
| Typical cycle length | Up to 18 months per FDA label; not recommended beyond 2 years cumulative anabolic therapy |
BioHack Track models Abaloparatide (Tymlos) at a half-life of 1.7 hours, so every dose you log is decayed against that curve and the app shows estimated active levels — not just what you typed.
No FDA-approved product for this compound is cited on this page, and no approved human dose is quoted. Treat the range below as research and community practice rather than a prescribed dose.
Supplied as a pre-filled pen; no reconstitution needed.
Refrigerate until first use; pen stable at room temperature for up to 30 days after opening.
Prescription medication with a boxed warning for osteosarcoma risk (based on rat data — clinical significance unknown). Should be followed by an antiresorptive agent to preserve gained bone density.
Track Abaloparatide (Tymlos) in BioHack Track. Half-life, dose range and route come pre-filled from this library — log a dose and the app counts your vial down, models what is in your system, and puts it on the same chart as your labs and body composition.
Evidence Check asks 10 questions about every compound. For Abaloparatide (Tymlos) it can answer 1 of them, from the papers we hold — graded by how strong the study design is, not by whether the findings are flattering. These are the same verdicts the app gives.
Meta-analyses or systematic reviews exist — the highest grade of evidence there is, whatever they conclude. Read them.
Research references only. Not medical advice, and not a recommendation to take anything.
These open a search of each database for Abaloparatide (Tymlos) — they are not citations, and nothing here is evidence for any particular dose. The same links are in the app.
6 papers naming Abaloparatide (Tymlos) in the title, drawn from PubMed and limited to reviews, meta-analyses and trials. Each was checked against PubMed’s own record for its title, journal and year. This is a starting point, not an evidence review — nothing here is offered as support for the dose range above, and the list is not exhaustive. See the editorial policy.
The half-life, route and dose range on this page are compiled from published pharmacokinetic literature, manufacturer and product monographs where one exists, and the ranges commonly reported in clinical and research use. They are kept as a range rather than a single figure because that is what the sources actually support — a half-life varies with route, formulation and the person.
These are not citations, and this page is not a review of the evidence. Where a number matters to you, follow the database links above and read the source. We say so plainly rather than dressing a compiled reference up as one.
Nothing on this page has been reviewed by a named clinician. It is a reference for people already tracking a protocol, not a recommendation to start one.
General reference compiled for use inside the app, not medical advice and not a recommendation to take anything. Dose ranges are what is commonly discussed, not a prescription. Talk to a qualified healthcare professional.